The stock has been pointing to a failed trial for a long time, and there seems to be a contingent that would like investors and potential investors to think that.
In the meantime, the SAP is hopefully being finalized, the trial will then be unblinded, and then we will see where we go from there. When we know what that data shows, we can determine if the trial has actually failed or succeeded, and not before.
The blinded data cited in the journal and by Linda Liau at SNO in 2018 looks to point towards a successful trial... so we shall see.